Based on these observations, we suggest that potent immunotherapy targeting Th17 cells and CD4+ CD25+ Foxp3+ Tregs and the inhibition of PGE2 secretion from HSC can slow the progress of LF and cirrhosis and other associated complications. This evidence concerns the gene FOXP3 and Cirrhosis.